A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice

NCT05254366 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2022

Last updated 2026-01-05

No results posted yet for this study

Summary

This is a non-interventional study of remazolam toluenesulfonate (rebenin ®) for injection in Chinese patients. A total of 2000 patients were enrolled in this study based on the preliminary safety assessment of rebenin ®, and all safety information was obtained

Conditions

  • Gastroscopic and Colonoscopic Sedation

Interventions

DRUG

Remimazolam Tosilate for Injection

Remimazolam Tosilate for Injection

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-30
Primary Completion
2023-02-08
Completion
2023-02-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05254366 on ClinicalTrials.gov